Equities research analysts expect that Celsion Co. (NASDAQ:CLSN) will report earnings per share of ($0.31) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Celsion’s earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.32). Celsion reported earnings of ($1.96) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 84.2%. The business is scheduled to report its next quarterly earnings report on Thursday, March 15th.
According to Zacks, analysts expect that Celsion will report full year earnings of ($2.46) per share for the current year. For the next financial year, analysts forecast that the company will report earnings of ($1.15) per share, with EPS estimates ranging from ($1.21) to ($1.08). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Celsion.
A number of equities research analysts have recently weighed in on the company. ValuEngine upgraded Celsion from a “strong sell” rating to a “sell” rating in a report on Saturday, December 9th. Oppenheimer assumed coverage on Celsion in a report on Tuesday, November 21st. They issued an “outperform” rating and a $9.00 price target for the company. Finally, Zacks Investment Research upgraded Celsion from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Celsion currently has a consensus rating of “Buy” and a consensus price target of $11.90.
Celsion (CLSN) traded up $0.12 during mid-day trading on Friday, reaching $2.37. The company’s stock had a trading volume of 95,549 shares, compared to its average volume of 354,812. Celsion has a 52 week low of $1.24 and a 52 week high of $6.06. The stock has a market cap of $39.90, a P/E ratio of -0.40 and a beta of 1.80.
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.